急性髓细胞白血病细胞CD34抗原表达的临床及生物学意义  

Clinical and biological significance of CD34 antigen expression in acute myeloid leukemia cells

作　　者：李建勇[1] 夏学鸣[1] 王爱青[1] 仇惠英[1] 薛永权[1] 阮长耿[1] 

机构地区：[1]苏州医学院附属第一医院,江苏省血液研究所苏州215006

出　　处：《实用肿瘤杂志》1997年第5期206-208,共3页Journal of Practical Oncology

摘　　要：为研究CD34在急性髓细胞白血病（AML）中的临床及生物学意义．用流式细胞术检测了107例AMLCD34表达。结果显示48．5％的患者CD34阳性表达．M3（15．8％）低于其他亚型（P＜0．05）。CD34+者肝脾肿大常见．CD34表达在t（8；21）、正常核型及t（15；17）组分别为72．0％、40．7％及17．6％。CD34+者的完全缓解率（41．9％）明显低于CD34-者的59．6％（P＜0．05）。结果提示CD34抗原可能是成人初治AML预后差的一个标志．To study CD34 antigen expression in acute myeloid leukemia(AML) cells and its relationship with clinicobiological features,CD34 expression was examined in 107 patients by indirect immunoflurescence method and flow cytometry. The results showed that CD34 antigen wasexpressed in 48. 5 % of cases and the positivity rate was higher in M 1 (6 2. 5 % ), M 2 (5 4. 9 % ), M 4 (71. 4 % ), M5 (50. 0% ) than that in M3 (15. 8% ) (P<0. 05 ). There was no significant difference in main clinicohematological features between CD34+ and CD34-AML (P> 0. 05), except heptosplenomegaly which was more frequently seen in CD34+ AML. The sequence of CD34 expression in patients which karyotype was performed from high to low was as follows: t(8; 21 )(72. 0% ), normal (40. 7 % ) and t(15 ; 17) (17. 6 % ). The complete remission rate was significantly higher in CD34- (59. 6% )than that of CD34+AML(41. 9% ) (P<0. 05). These suggested that CD34 antigen may be an index of poor responce to treatment in AML.

关 键 词：急性 髓细胞性 白血病 染色体 CD34抗原 

分 类 号：R733.71[医药卫生—肿瘤]